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Preliminary Clinical Description of Severe Acute Respiratory Syndrome
Severe acute respiratory syndrome (SARS) is a condition of unknown etiology that has been described in patients in Asia, 
North America, and Europe. This report summarizes the clinical description of patients with SARS based on information 
collected since mid-February 2003 by the World Health Organization (WHO), Health Canada, and CDC in collaboration with 
health authorities and clinicians in Hong Kong, Taiwan, Bangkok, Singapore, the United Kingdom, Slovenia, Canada, and the 
United States. This information is preliminary and limited by the broad and necessarily nonspecific case definition.
As of March 21, 2003, the majority of patients identified as having SARS have been adults aged 25--70 years who were 
previously healthy. Few suspected cases of SARS have been reported among children aged <15 years.
The incubation period for SARS is typically 2--7 days; however, isolated reports have suggested an incubation period as long 
as 10 days. The illness begins generally with a prodrome of fever (>100.4°F [>38.0°C]). Fever often is high, sometimes is 
associated with chills and rigors, and might be accompanied by other symptoms, including headache, malaise, and myalgia. At 
the onset of illness, some persons have mild respiratory symptoms. Typically, rash and neurologic or gastrointestinal findings 
are absent; however, some patients have reported diarrhea during the febrile prodrome.
After 3--7 days, a lower respiratory phase begins with the onset of a dry, nonproductive cough or dyspnea, which might be 
accompanied by or progress to hypoxemia. In 10%--20% of cases, the respiratory illness is severe enough to require 
intubation and mechanical ventilation. The case-fatality rate among persons with illness meeting the current WHO case 
definition of SARS is approximately 3%.
Chest radiographs might be normal during the febrile prodrome and throughout the course of illness. However, in a substantial 
proportion of patients, the respiratory phase is characterized by early focal interstitial infiltrates progressing to more 
generalized, patchy, interstitial infiltrates. Some chest radiographs from patients in the late stages of SARS also have shown 
areas of consolidation.
Early in the course of disease, the absolute lymphocyte count is often decreased. Overall white blood cell counts have 
generally been normal or decreased. At the peak of the respiratory illness, approximately 50% of patients have leukopenia and 
thrombocytopenia or low-normal platelet counts (50,000--150,000/| jL). Early in the respiratory phase, elevated creatine 
phosphokinase levels (as high as 3,000 IU/L) and hepatic transaminases (two to six times the upper limits of normal) have 
been noted. In the majority of patients, renal function has remained normal.
The severity of illness might be highly variable, ranging from mild illness to death. Although a few close contacts of patients 
with SARS have developed a similar illness, the majority have remained well. Some close contacts have reported a mild, 
febrile illness without respiratory signs or symptoms, suggesting the illness might not always progress to the respiratory phase.
Treatment regimens have included several antibiotics to presumptively treat known bacterial agents of atypical pneumonia. In 
several locations, therapy also has included antiviral agents such as oseltamivir or ribavirin. Steroids have also been 
administered orally or intravenously to patients in combination with ribavirin and other antimicrobials. At present, the most 
efficacious treatment regimen, if any, is unknown.
In the United States, clinicians who suspect cases of SARS are requested to report such cases to their state health 
departments. CDC requests that reports of suspected cases from state health departments, international airlines, cruise ships, 
or cargo carriers be directed to the SARS Investigative Team at the CDC Emergency Operations Center, telephone 770-488­
7100. Outside the United States, clinicians who suspect cases of SARS are requested to report such cases to their local public 
health authorities. Additional information about SARS (e.g., infection control guidance and procedures for reporting suspected 
cases) is available at http://www.cdc.gov/ncidod/sars. Global case counts are available at http://www.who.int.
Reported by: World Health Organization, Geneva, Switzerland. Immunization and Respiratory Infections Div, Centre for 
Infectious Disease Prevention and Control, Health Canada, Ottawa, Canada. CDC SARS Investigation Team; TA Clark, MD, 
and B Park, MD, EIS officers, CDC.
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